- 32. Process according to claim 28, characterized in that the sensory cells of the inner ear are hair sensor cells.
- 33. Process according to claim 28, characterized in that the cell cycle inhibitor is a cyclin-dependent kinase inhibitor.
- 34. Process according to claim 33, characterized in that the cyclin-dependent kinase inhibitor is the cyclin-dependent kinase inhibitor $p27^{kip1}$.
- 35. Process according to claim 28, characterized in that the disease or disorder of the inner ear is a perceptive deafness.
- 36. Process according to claim 28, characterized in that the active ingredient is a least one peptide or at least one protein.
- 37. Process according to claim 28, characterized in that the active ingredient is at least one nucleic acid molecule.
- 38. Process according to claim 37, characterized in that the nucleic acid molecule codes for a peptide or a protein.
- 39. Process according to claim 37, characterized in that the nucleic acid molecule is a DNA molecule.
- 40. Process according to claim 39, characterized in that the nucleic acid molecule is a cDNA molecule.
- 41. Process according to claim 37, characterized in that the nucleic acid molecule is a RNA molecule.
- 42. Process according to claim 28, characterized in that the active ingredient is in the form of a vector.
- 43. Process according to claim 42, characterized in that the vector is a viral vector.
- 44. Process according to claim 43, characterized in that the virus is a retrovirus, an adenovirus or an adeno-associated virus.
- 45. Process according to claim 42, characterized in that the vector is a non-viral vector.
- 46. Process according to claim 37, characterized in that it is a nucleic acid molecule packed in a liposome or a lipoplex.

500/

47. Process according to claim 28, characterized in that the active ingredient is used in a therapeutically active quantity.

- 48. Process according to claim 28, characterized in that the active ingredient is intended for local application.
- 49. Active ingredient for regenerating the sensory cells of the inner ear, characterized in the it is in a position to at least partly inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear.
- 50. Active ingredient according to claim 49, characterized in that the cell cycle inhibitor is a cyclin-dependent kinase inhibitor.
- 51. Active ingredient according to claim 49, characterized in that it is at least one peptide or at least one protein.
- 52. Active ingredient according to claim 49, characterized in that it is a least one nucleic acid molecule.
- 53. Active ingredient according to claim 52, characterized in that the nucleic acid molecule is selected from the group consisting of a DNA molecule, cDNA molecule or RNA molecule.
- 54. Active ingredient according to claim 49, characterized in that the active ingredient is in the form of a vector or vehicle.
- 55. Pharmaceutical composition or medicament, characterized in that it contains at least one active ingredient able to inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear in an active quantity and a pharmaceutically acceptable carrier.
- 56. Pharmaceutical composition or medicament according to claim 55, characterized in that the active ingredient is an active ingredient according to claim 50.
- 57. Process according to claim 37 wherein said nucleic acid molecule is recombined nucleic acid molecule.
- 58. Process according to claim 12 wherein said vector carries a nucleic acid molecule.
- 59. Active ingredient according to claim 49 wherein the sensory cells regenerated are happy sensory cells.
- 60. Active ingred ent according to claim 50 wherein said cyclin-dependent kinase inhibitor is p27kip1.

Floor

500